miR-205与乳腺癌关系的研究进展

Research progress in correlation of miR-205 and breast cancer

微小RNA(miRNAs)作为一类进化保守的非编码RNAs,通过与靶基因mRNA的序列互补配对抑制其翻译或启动降解来发挥作用。越来越多的研究结果证实,miRNAs通过发挥促癌或抑癌作用参与调控多种肿瘤的发生与发展。其中mi R-205在乳腺癌组织中表达普遍降低,将miR-205在乳腺癌细胞中过表达,则其能够通过抑制表皮生长因子受体3(ERBB3)、锌指E-盒结合同源异形盒(ZEB)1、ZEB2、血管内皮生长因子A(VEGFA)等靶基因的表达,从而抑制癌细胞增殖、转移与侵袭能力,最终影响乳腺癌的治疗敏感性与预后。本综述重点阐述了miR-205在乳腺癌中对细胞增殖、凋亡、侵袭、转移等相关基因及信号通路的调控作用与机制,miR-205与乳腺癌患者治疗敏感性以及患者预后的相关性,以期为乳腺癌的诊断、治疗及预后判断提供新的思路与治疗靶点。

As evolutionarily conservative small non-coding regulatory RNAs, micro RNAs(miRNAs) are capable ofsilencing gene expression by translational repression or m RNA degradation through complementary base pairing with them RNA of target genes. Accumulating evidence indicates that deregulation of miRNAs is often associated with humanmalignancies because miRNAs can function as oncogenes or tumor suppressors. Among them, miR-205 is significantlyunderexpressed in breast tumors. Overexpression of miR-205 in breast cancer cells significantly inhibits cell proliferation,invasion and metastasis through repressing the expression of human epidermal growth factor receptor 3(ERBB3), zinc fingerE-box binding homeobox 1(ZEB1), zinc finger E-box binding homeobox 2(ZEB2), vascular endothelial growth factor A(VEGFA) and other target genes, which affects therapeutic sensitivity and prognosis of breast cancer patients. This articlereviews the role and regulation of miR-205 in breast cancer, the value of miR-205 in clinical application and miR-205 related research progress, which is expected to provide new strategy and therapeutic target for breast cancer diagnosis,treatment and prognosis.